Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion’s 100% subsidiary, Celltrion USA, Inc., has updated its total capital raising amount to USD 516.1M after reducing its second tranche payment (from USD 86.3M to USD 70.3M) and finalizing the payment date for May 13, 2026.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Decision on Paid-in Capital Increase (Major Management Matters of Subsidiary) (Correction)
- Original Disclosure Date: December 11, 2025 (Correction Filing Date: May 8, 2026 / DART Filing Date: May 11, 2026)
- Reason for Correction: Adjustment of the 2nd tranche amount and finalization of the payment date
- Target Subsidiary: Celltrion USA, Inc. (U.S., 100% owned subsidiary of Celltrion)
- Purpose & Corrected Capital Raising Amounts:
- Total Funds Raised: (Before) USD 532,100,000 (KRW 782.4B) → (After) USD 516,100,000 (KRW 758.9B based on initial FX rate USD/KRW 1,470.40)
- Working Capital: USD 7,000,000 (KRW 10.3B) — Unchanged
- Acquisition of Shares in Other Entities: (Before) USD 525,100,000 (KRW 772.1B) → (After) USD 509,100,000 (KRW 748.6B)
- Payment Schedule by Tranche (Total USD 516.1M):
- 1st Tranche: USD 445,800,000 (Completed, Scheduled Date: December 18, 2025)
- 2nd Tranche: (Before) USD 86,300,000 (Within 2026) → (After) USD 70,300,000 (May 13, 2026)
- Method & New Share Issuance: Rights offering to existing shareholder (Issuance of 100 common shares and capital contribution without share issuance)
- Par Value & Issue Price per Share: USD 0.0001 (KRW 0.15)
- Board Resolution Date: December 11, 2025
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of 2nd Tranche Capital Injection Completion and Periodic Reports
This corrected disclosure specifies the final payment amount and deadline (May 13, 2026) for the second tranche of Celltrion USA, Inc.’s rights offering, making it important to confirm whether the capital payment is completed as scheduled. Tracking the full execution of the capital contribution according to the updated schedule is essential to verify the complete settlement of the transaction. Final payment execution can be verified under ‘Matters Related to Subsidiaries’ and ‘Notes to Consolidated Financial Statements’ in upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
